Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

BACKGROUND: Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. This study developed a prognostic nomogram and a calculator to predict the prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Saigusa, Yusuke, Yoneyama, Shuko, Kato, Masashi, Kojima, Ippei, Yamada, Hiroshi, Kamihira, Osamu, Tabata, Kenichi, Tsumura, Hideyasu, Iwamura, Masatsugu, Makiyama, Kazuhide, Uemura, Hiroji, Miyoshi, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990312/
https://www.ncbi.nlm.nih.gov/pubmed/36882764
http://dx.doi.org/10.1186/s12885-023-10700-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990312/
https://www.ncbi.nlm.nih.gov/pubmed/36882764
http://dx.doi.org/10.1186/s12885-023-10700-0

Ejemplares similares